| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/08/2004 | DE10224844A1 Nicht-peptidische BRS-3-Agonisten Non-peptidic BRS-3 agonist |
| 01/08/2004 | DE10057290B4 Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten To be administered enterally supplement for parenteral nutrition or partial enteral / oral nutrition in critically ill patients, chronically ill and malnourished |
| 01/08/2004 | CA2744893A1 Aryl carbonyl derivatives as glucokinase activators |
| 01/08/2004 | CA2493854A1 Phosphodiesterase inhibitor |
| 01/08/2004 | CA2493646A1 Caspase inhibitors and uses thereof |
| 01/08/2004 | CA2491002A1 Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
| 01/08/2004 | CA2490411A1 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | CA2490261A1 Differentiation modulating agents and uses therefor |
| 01/08/2004 | CA2490250A1 Drug composition for blood sugar control |
| 01/08/2004 | CA2490138A1 Novel tetrahydropyridine derivatives as renin inhibitors |
| 01/08/2004 | CA2490079A1 Purified amylase inhibitor and novel process for obtaining the same |
| 01/08/2004 | CA2490016A1 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 01/08/2004 | CA2489942A1 Satiety inducing composition |
| 01/08/2004 | CA2489660A1 Drug composition for prevention or inhibition of advance of diabetic complication |
| 01/08/2004 | CA2489560A1 Substituted quinoline ccr5 receptor antagonists |
| 01/08/2004 | CA2489376A1 Methods of organ regeneration |
| 01/08/2004 | CA2489090A1 Nutritional composition for detoxification and cancer prevention |
| 01/08/2004 | CA2488526A1 Stable liquid parenteral parecoxib formulation |
| 01/07/2004 | EP1378573A1 Interleukin 1 beta protease and interleukin 1 beta protease inhibitors |
| 01/07/2004 | EP1378517A1 Phosphoinositolglycan (PIG) binding protein from adipocytes |
| 01/07/2004 | EP1378510A1 Triazaspiro 5.5]undecane derivatives and drugs containing the same as the active ingredient |
| 01/07/2004 | EP1378508A1 Various forms of paroxetine hydrochloride anhydrate |
| 01/07/2004 | EP1378507A2 Process for producing optically active imidazole compounds, intermediates for synthesizing the same, and process for producing the same |
| 01/07/2004 | EP1377834A2 Medicaments which are modulators of hm74 and/or hm74a activity |
| 01/07/2004 | EP1377676A2 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 01/07/2004 | EP1377610A2 Osteoprotegerin in milk |
| 01/07/2004 | EP1377609A2 Mhc molecule constructs and their uses for diagnosis and therapy |
| 01/07/2004 | EP1377593A2 2-amino-propanol derivatives |
| 01/07/2004 | EP1377579A2 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
| 01/07/2004 | EP1377574A1 6-phenylbenzonaphthyridines |
| 01/07/2004 | EP1377573A2 Pyrazolopyridine derivatives |
| 01/07/2004 | EP1377572A1 Isoxaxole derivatives as inhibitors of src and other protein kinases |
| 01/07/2004 | EP1377570A1 Substituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and the use of the same as selective ligands of the adenosine receptor |
| 01/07/2004 | EP1377569A1 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations |
| 01/07/2004 | EP1377559A2 Rxr activating molecules |
| 01/07/2004 | EP1377550A1 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors |
| 01/07/2004 | EP1377545A1 Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae |
| 01/07/2004 | EP1377540A1 INHIBITORS OF INTEGRIN AvB6 |
| 01/07/2004 | EP1377295A2 Carboxamide derivatives as therapeutic agents |
| 01/07/2004 | EP1377293A1 Aryl and biaryl piperidines used as mch antagonists |
| 01/07/2004 | EP1377290A2 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 01/07/2004 | EP1377288A1 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method |
| 01/07/2004 | EP1377287A2 Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases |
| 01/07/2004 | EP1377284A1 Controlled release arginine formulations |
| 01/07/2004 | EP1377283A2 Compounds of the formula r1-x-y-z-nr2r3 as abca-1 elevating agents against coronary artery disease or atherosclerosis |
| 01/07/2004 | EP1377282A2 Aryl-n-cyanoguanidines and methods related thereto |
| 01/07/2004 | EP1377280A2 Bulking agents as satiety agents |
| 01/07/2004 | EP1377278A1 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv |
| 01/07/2004 | EP1377277A1 Pharmaceutical compositions comprising pravastatin for reducing ldl cholesterol levels |
| 01/07/2004 | EP1377276A2 Timed pulse release composition |
| 01/07/2004 | EP1377183A1 Cactaceae-based formulation having the property of fixing fats, and method for obtaining same |
| 01/07/2004 | EP1377181A1 Improved edible compositions for lowering cholesterol |
| 01/07/2004 | EP1289997B1 Macrolides |
| 01/07/2004 | EP1227736B1 Protein hydrolysates produced with the use of marine proteases |
| 01/07/2004 | EP1175417B1 Substituted benzolactam compounds |
| 01/07/2004 | EP1019082B1 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 01/07/2004 | EP0944611B1 Dimesylate salts of neuropeptide y ligands |
| 01/07/2004 | EP0909132B1 Dietetic baby food formula containing conjugated linoleic acids |
| 01/07/2004 | EP0748315B1 Use of imidazole derivatives for treating disorders involving angiotensin receptors at1 and at2, these products, preparation thereof, use thereof as drugs, and pharmaceutical compositions containing same |
| 01/07/2004 | EP0661992B1 Pharmaceutical formulations of interleukin-1 inhibitors |
| 01/07/2004 | EP0600880B1 Interleukin 1- beta protease and interleukin 1-beta protease inhibitors |
| 01/07/2004 | CN1466594A Polysaccharides with antithrombotic activity comprising at least a covalent bono with biotin or a biotin derivative |
| 01/07/2004 | CN1466590A Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same |
| 01/07/2004 | CN1466585A Sodium sal ts of 5'-4'-2-(N-methyl-N-(2-pyridyl)amino) ethoxy [benzyl] thiazolidine-2,4-dione |
| 01/07/2004 | CN1466584A Tetrazolyl-phenyl acetamide glucokinase activators |
| 01/07/2004 | CN1466467A Pharmaceutical composition and method for treating hypogonadism |
| 01/07/2004 | CN1466465A Preventives or remedies for obesity or fatty liver |
| 01/07/2004 | CN1466458A Use of arginine in the preparation of a medicament for the prevention and treatment of the side effcts associated with the intravenous administration |
| 01/07/2004 | CN1466451A Ion-strength independent sustained release pharmacetuical formulation |
| 01/07/2004 | CN1465703A Synthesis, expression, preparation and application for human parathyroid hormone gene mutant |
| 01/07/2004 | CN1465693A Ostrica bone medicinal liquor and preparation method thereof |
| 01/07/2004 | CN1465399A Lipid reducing and regulating agent |
| 01/07/2004 | CN1465397A Novel medicine for treating diabetes and chronic complicating disease thereof |
| 01/07/2004 | CN1465379A Oral liquor for treating diabetes and preparation method thereof |
| 01/07/2004 | CN1465368A Black boned chicken active capsule and preparation process thereof |
| 01/07/2004 | CN1465366A Novel pomegranate leaf extract and medicinal use thereof |
| 01/07/2004 | CN1465361A Cooling and fat-reducing lotus throne juice |
| 01/07/2004 | CN1465359A Tea and Chinese wolfberry fruit extracts composition and use thereof |
| 01/07/2004 | CN1465347A Edible cellulose preparation |
| 01/07/2004 | CN1465343A Medical cure use of 17-allyl-4,5ÔÇÿalphaÔÇÖ-epoxy-3, 14-dihydroxymorphinan-6 keto hydrochloride |
| 01/07/2004 | CN1465342A Thiazolidine salt derivative hypoglycemic medicine |
| 01/07/2004 | CN1465297A Calcium-enriching beverage and preparation process thereof |
| 01/07/2004 | CN1133647C Heterocyclic compound used as leucocyte adherence inhibitor and VLA-4 antagonist |
| 01/07/2004 | CN1133627C Intermediate of N-benzyl dioxothiazolidinyl benzoyl amide derivatives, and its prepn. method |
| 01/07/2004 | CN1133623C Process for producing optically active imidazole compound, intermediates for synthesizing samke and mfg method |
| 01/07/2004 | CN1133444C Preparing process for powdered medicine for reducing blood fat |
| 01/07/2004 | CN1133435C Oral composition containing dehydroepiandrosterone and its sodium sulfate |
| 01/07/2004 | CN1133431C Treatment of diabetes with rosiglitazone and insulin |
| 01/07/2004 | CN1133427C Solid oral dosage forms of valsartan |
| 01/07/2004 | CN1133405C Products capable of emitting far infrared ray and method for using far infrared ray |
| 01/06/2004 | US6673838 Succinate salt of O-desmethyl-venlafaxine |
| 01/06/2004 | US6673803 Quinazoline derivatives and pharmaceutical compositions containing them |
| 01/06/2004 | US6673798 PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 01/06/2004 | US6673782 Treating proteinuria and swollen lymph node symptoms by administering an effective dose of a vitamin d analog to a patient on a diet which includes a calcium intake level of >800mg/day per 160 pound patient |
| 01/06/2004 | US6673780 Such as 4-(4-(3-hydroxy-3-methyl-butane-1-sulfinylmethyl)-phenylmethanesulfinyl)-2 -methyl-butan1-ol for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders |
| 01/06/2004 | US6673777 Guanylhydrazones useful for treating diseases associated with T cell activation |
| 01/06/2004 | US6673574 Oral delivery of peptides using enzyme-cleavable membrane translocators |
| 01/06/2004 | US6673555 Methods of using SCAP antagonists |
| 01/06/2004 | US6673382 Containing sugar to provide freezing and thawing stability; foods, drinks; treatment of anemia |
| 01/06/2004 | US6673381 Such as (6s)-tetrahydrofolic acid, and the 5-methyl, 5- or 10-formyl, 5,10-methylene, 5,10-methenyl, or 5-formimino derivatives; increasing folate intake such as to prevent birth defects |